Inthis regard, in the case of HER2− BC, it is important that we search forpredictive markers of complete and partial regression, in contrast to pCRmarkers in the triple-negative (TN) and HER2+ BC subtypes. The gene discussed is ERBB2; the disease is breast cancer.